|
rs1001179
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analyses revealed a significant association between the rs1001179 polymorphism and prostate cancer in all models except the homozygote comparison.
|
27449288 |
2016 |
|
rs10012
|
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In summary, this meta-analysis suggests that Leu432Val polymorphism is associated with ovarian cancer, lung cancer, and endometrial cancer risk; Asn453Ser and Arg48Gly polymorphisms are associated with endometrial cancer risk among Caucasians, Ala119Ser polymorphism is associated with prostate cancer risk, and Ala119Ser polymorphism is associated with breast cancer risk in Caucasians.
|
25475389 |
2015 |
|
rs10012
|
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
A common C-G-C-C-G-A haplotype for rs2567206-rs2551188-rs2617266-rs10012-rs1056836-rs1800440 showed an inverse association with PCa risk in Hispanic Caucasians (OR = 0.19, P = 0.04, 95% CI = 0.04-0.95) and with aggressive disease status (i.e.
|
18544568 |
2008 |
|
rs1004072779
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Significant association of TMPRSS2-ERG fusion-positive PCa was found with rare variants in the genes for POLI [variant F532S: P = 0.0011; odds ratios (OR), 4.62; 95% confidence interval (95% CI), 1.84-11.56] and ESCO1 (variant N191S: P = 0.0034; OR, 4.27; 95% CI, 1.62-11.28).
|
19861517 |
2009 |
|
rs10046
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The combination of the TTTA long repeats and the minor alleles of rs10046 in CYP19A1 and rs2077647 in ESR-alpha was a high risk for prostate cancer despite greater than or equal to 60 mg isoflavones/day.
|
19952760 |
2010 |
|
rs10069690
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The T allele of the intron 4 SNP (rs10069690) was found to be significantly associated with a decreased risk for an aggressive form of PCa (OR=0.76; 95% CI: 0.59-0.97; P=0.030).
|
25738283 |
2015 |
|
rs10090154
|
|
Prostate carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
The cumulative effects test of risk alleles (rs rs1983891, rs339331, rs16901966, rs1447295 and rs</span>10090154) showed an increasing risk to PCa in a frequency-dependent manner (ptrend=0.001), and men with more than 3 risk alleles had the most significant susceptibility to PCa (OR=1.99, p=0.001), compared with those who had one risk allele (OR=1.17, p=0.486).
|
26537068 |
2016 |
|
rs10090154
|
|
Prostate carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
The risk alleles rs16901966, rs1447295 and rs10090154 were associated with age at diagnosis and tumor stage as compared with controls, while rs16901966 was associated with aggressive PCa (OR 1.43, 95% CI 1.01-2.03, p=0.042).
|
24377597 |
2014 |
|
rs10090154
|
|
Prostate carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
For northern Chinese men rs16901966, rs1447295, rs11986220 and rs10090154 at 8q24 (region 1, region 2) are associated with prostate cancer and prostate cancer related clinical covariates.
|
22099997 |
2012 |
|
rs10090154
|
|
Prostate carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Therefore, this meta-analysis demonstrated that 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) were associated with the susceptibility to PCa, which held the potential biomarkers for PCa risk.
|
29158792 |
2017 |
|
rs10090154
|
|
Prostate carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
We showed statistically significant association of the A allele of rs1447295 (OR [CI 95%] = 1.96 [1.37-2.81], P<0.0001) and the T allele of rs10090154 (OR [CI 95%] = 2.14 [1.41-3.26], P<0.0001) with CaP.
|
23628314 |
2014 |
|
rs10090154
|
|
Prostate carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Four GWAS replication SNPs (rs2660753, rs13254738, rs10090154, rs2735839) and seven flanking SNPs were associated with CaP aggressiveness (P < 0.05) in three genomic regions: One at 3p12 (EA), seven at 8q24 (5 AA, 2 EA), and three at 19q13 at the kallilkrein-related peptidase 3 (KLK3) locus (two AA, one AA and EA).
|
22549899 |
2013 |
|
rs10090154
|
|
Prostate carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
We genotyped three variants associated with prostate cancer (rs10090154, rs13254738, and rs7000448), one associated with both prostate and colorectal cancer (rs6983267), and one associated with breast cancer (rs13281615) in a series of 1,499 breast cancer cases and 1,390 controls.
|
18349290 |
2008 |
|
rs1012477
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our results showed that at least one SNP in nine core circadian genes (rs885747 and rs2289591 in PER1; rs7602358 in PER2; rs1012477 in PER3; rs1534891 in CSNK1E; rs12315175 in CRY1; rs2292912 in CRY2; rs7950226 in ARNTL; rs11133373 in CLOCK; and rs1369481, rs895521, and rs17024926 in NPAS2) was significantly associated with susceptibility to prostate cancer (either overall risk or risk of aggressive disease), and the risk estimate for four SNPs in three genes (rs885747 and rs2289591 in PER1, rs1012477 in PER3, and rs11133373 in CLOCK) varied by disease aggressiveness.
|
19934327 |
2009 |
|
rs10165970
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs10175368
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results demonstrate smoking and alcohol consumption to modify the risks of CYP1B1 polymorphisms for prostate cancer which may be through rs10175368, and this is of importance in understanding their role in the pathogenesis and as a biomarker for this disease.
|
30133114 |
2018 |
|
rs1024611
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a case-control study to analyze the frequencies of CCL2 (I/D, rs3917887), -2518 (A > G, rs1024611), and CCR2 (G > A, rs1799864) polymorphisms for prostate cancer (PCa) risk.
|
25266801 |
2015 |
|
rs103294
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
In addition to confirming several associations reported in other ancestry groups, this study identified two new risk-associated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10(-14)) and 19q13.4 (rs103294, P = 5.34 × 10(-16)) in 4,484 prostate cancer cases and 8,934 controls.
|
23023329 |
2012 |
|
rs103294
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
A recent prostate cancer (PCa) genome-wide association study (GWAS) identified rs103294, a single nucleotide polymorphism (SNP) located on LILRA3, a key component in the regulation of inflammatory inhibition, to be significantly associated with PCa risk in a Chinese population.
|
23615473 |
2013 |
|
rs103294
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Three SNPs-rs2735839, rs10486567, and rs103294-were associated with biopsy-proven high-aggressive (GS ≥8) prostate cancer (P < 0.05).
|
25274378 |
2014 |
|
rs1034528
|
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In the single-locus analysis, we found a significantly increased risk of PCa associated with mTOR rs2536 CT/CC and rs1034528 CG/CC genotypes [adjusted OR = 1.42 (1.13-1.78), P = 0.003 and 1.29 (1.07-1.55), P = 0.007), respectively], compared with their common homozygous genotypes, whereas mTOR rs2295080 GT/GG genotypes were associated with a decreased risk of PCa [adjusted OR = 0.76 (0.64-0.92), P = 0.003], compared with wild-type TT genotypes.
|
23940798 |
2013 |
|
rs1034866440
|
|
Prostate carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs1034866440
|
|
Prostate carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
rs1034866440
|
|
Prostate carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs1034866440
|
|
Prostate carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17.
|
11571725 |
2001 |